Related Experiment Videos

Enhancement of endotoxin activity by muramyldipeptide

Haruhiko Takada1, Shigekuni Yokoyama, Shuhua Yang

  • 1Department of Microbiology and Immunology, Tohoku University School of Dentistry, Sendai, Japan. dent-ht@mail.cc.tohoku.ac.jp

Insights

Synthetic muramyldipeptide (MDP) primes mice to enhance inflammatory responses to bacterial components, acting independently of Toll-like receptors (TLRs) and interferon-gamma. This priming occurs through both parenteral and oral administration routes.

Area of Science:

  • Immunology
  • Microbiology
  • Pharmacology

Background:

  • Synthetic muramyldipeptide (MDP) is the minimal structural unit of bacterial peptidoglycan responsible for adjuvant activities.
  • Bacterial components like lipopolysaccharide (LPS) can induce lethal shock in susceptible individuals.
  • Understanding immune priming mechanisms is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To investigate the immune-priming effects of synthetic muramyldipeptide (MDP) in mice.
  • To elucidate the mechanisms underlying MDP-induced sensitization to bacterial components.
  • To explore the role of Toll-like receptors (TLRs) and interferon-gamma in MDP-mediated immune responses.

Main Methods:

  • Mice were sensitized with MDP and subsequently challenged with LPS to assess shock responses.
  • Cytokine production was measured in response to various bacterial components in MDP-primed mice.
  • Human monocytic THP-1 cells were used to study MDP activation and synergistic effects with TLR agonists.
  • TLR2 knockout and TLR4-mutated mice were employed to investigate the role of specific TLRs in MDP priming.

Main Results:

  • MDP sensitized mice to both early anaphylactoid and late endotoxin shock induced by LPS.
  • MDP-primed mice exhibited enhanced inflammatory cytokine production upon stimulation with bacterial components.
  • MDP activated THP-1 cells independently of CD14, TLR2, and TLR4, increasing MyD88 expression.
  • MDP showed synergistic cytokine induction with TLR4, TLR2, and TLR9 agonists in THP-1 cells.
  • MDP primed TLR2 knockout mice but not TLR4-mutated mice to enhance tumor necrosis factor-alpha production upon lipid A stimulation.
  • MDP-induced priming was independent of interferon-gamma.

Conclusions:

  • Synthetic muramyldipeptide (MDP) acts as an immune priming agent, enhancing responses to bacterial components through both parenteral and oral routes.
  • MDP's priming activity involves MyD88 upregulation and synergistic cytokine induction with various TLR agonists, independent of TLR2 and TLR4 in initial activation.
  • The priming effect is observed in TLR2 knockout mice but not in TLR4-mutated mice, suggesting a complex interplay with TLR signaling pathways.
  • MDP-mediated immune priming occurs independently of interferon-gamma, differentiating it from other known priming systems.

Related Concept Videos